Physician profile
Charles E Sheehan
NPI 1891871109
$348.29
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $86.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.05 | 2019 | |
| Merck Sharp & Dohme LLC | $31.92 | 2019 | |
| Pfizer INC. | $28.35 | 2019 | |
| Allergan, INC. | $25.78 | 2019 | |
| Lilly USA, LLC | $25.21 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.79 | 2019 | |
| Amgen INC. | $17.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.02 | 2019 | |
| Shire North American Group INC | $14.38 | 2019 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Abbvie INC. | $13.37 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sheehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.